Bioniche



May 13, 2013 Bioniche Engages Evercore Partners to Assist in the Divestment of its Animal Health Business May 8, 2013 Bioniche Life Sciences Inc. Reports Q3, Fiscal 2013 Results
Latest TSX stock price All prices delayed at least 15 minutes. Source: TSX Inc. Latest ASX stock price All prices delayed at least 20 minutes. Source: ASX Inc.

Human Health News Release

Bioniche to Host Bladder Cancer Roundtable

27/03/06

-- Tuesday, March 28th in New York City --

BELLEVILLE ON, March 27, 2006 – Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company (TSX: BNC), will be hosting a:

Bladder Cancer Roundtable

Tuesday, March 28, 2006
12:00 p.m. to 2:00 p.m. (EST)
at the Canadian Consulate General
(1251 Avenue of the Americas – New York City)

The Roundtable will present the global incidence of bladder cancer and its current treatments; the Mycobacterial Cell Wall-DNA Complex (MCC) platform; the clinical history of MCC in bladder cancer; the Phase III protocols for the refractory study and pivotal trial; and perspectives on bladder cancer from a principal investigator.

The following individuals will make presentations:

Graeme McRae, President & Chief Executive Officer, Bioniche Life Sciences
Dr. Nigel Phillips, Chief Scientific Officer, Bioniche Life Sciences
Dr. Francois Charette, Chief Medical Officer, Bioniche Life Sciences
Dr. Alvaro Morales, Urologist and International Principal Investigator, Queen’s University
Dr. Harry Herr, Urologist and North American Principal Investigator, Memorial Sloan-Kettering Cancer Center and The New York Hospital – Cornell Medical Center

A listen-only audio web cast will be available here.

The web cast will be available for replay using the above links for 90 days following the event.

###

Back

Categories:
All Releases
Archived Releases
Animal Health
Corporate
Financial
Human Health
One Health